Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

August

5

electroCore Announces Second Quarter 2021 Financial Results

Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020...

27

electroCore Announces Issuance of New Patent for Migraine Treatment Using Smartphones

Newly allowed patent is latest U.S. patent to issue in connection with electroCore’s non-invasive development program...

16

electroCore to Join Russell Microcap® Index

Effective after the open of trading on June 28, 2021 ROCKAWAY, NJ, June 16, 2021 (GLOBE...

23

electroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe

Silvert Medical will serve as exclusive distributor of gammaCore Sapphire™ in Belgium, Luxembourg, the Netherlands, and France...

15

Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms

ROCKAWAY, N.J.–(BUSINESS WIRE)–Mar. 15, 2021– Amid the vaccine rollout, 97,309 new cases of COVID-19...

16

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine

FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine...

26

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

RSK Medical will serve as exclusive distributor of the gammaCore Sapphire™ in Canada, supplying therapy...

19

electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”

Decision covering gammaCore Sapphire™ D will go into effect April 1, 2021 ROCKAWAY, N.J., Jan. 19,...

8

electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study

All study endpoints showed benefit from non-invasive vagus nerve stimulation, with many endpoints showing...

24

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

Reimbursement for gammaCore™ in England BASKING RIDGE, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR),...

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

Paper supports use of nVNS as a front-line therapy for acute and preventative treatment...

27

electroCore Announces Board of Directors Transition

Michael Atieh to assume chairmanship effective April 1, 2020 December 27, 2019 at 10:06...

Recent developments

News

August

5

electroCore Announces Second Quarter 2021 Financial Results

July

27

electroCore Announces Issuance of New Patent for Migraine Treatment Using Smartphones

June

16

electroCore to Join Russell Microcap® Index

March

23

electroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe

March

15

Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms

February

16

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine

January

26

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

January

19

electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”

December

8

electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study

August

24

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

July

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

December

27

electroCore Announces Board of Directors Transition